The latest price target for Akoya Biosciences (NASDAQ:AKYA) was reported by Piper Sandler on August 13, 2024. The analyst firm set a price target for $4.00 expecting AKYA to rise to within 12 months (a possible 40.85% upside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Akoya Biosciences (NASDAQ:AKYA) was provided by Piper Sandler, and Akoya Biosciences maintained their overweight rating.

There is no last upgrade for Akoya Biosciences

The last downgrade for Akoya Biosciences Inc happened on August 6, 2024 when Morgan Stanley changed their price target from $4 to $3 for Akoya Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akoya Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akoya Biosciences was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.

While ratings are subjective and will change, the latest Akoya Biosciences (AKYA) rating was a maintained with a price target of $6.00 to $4.00. The current price Akoya Biosciences (AKYA) is trading at is $2.84, which is out of the analyst’s predicted range.